Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stent showdown: which Drug-Coated device keeps heart arteries open longer?

NCT ID NCT00960648

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at over 3000 people with coronary artery disease to compare two types of drug-eluting stents: everolimus-eluting (Xience/Promus) and sirolimus-eluting (Cypher). The goal was to see which one better prevents major heart problems like heart attacks or the need for repeat procedures. Researchers tracked patients for several years to measure safety and long-term effectiveness in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
drug-eluting stents (everolimus-eluting stent and sirolimus-eluting stent)
What this could lead to
If successful, this could confirm that everolimus-eluting stents are as safe and effective as sirolimus-eluting stents for treating blocked heart arteries.
What could go wrong
This is a completed registry study, not a randomized trial, so results may be less definitive. Stents carry risks like blood clots or re-narrowing of the artery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,056 people

The number who actually took part.

Started

Apr 2008

Finished

Jan 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 4000 patients derived from a population of patients receiving percutaneous coronary intervention for ischemic heart disease will be enrolled in the present registry.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient agrees to participate in this study by signing the informed consent form. * Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form. Exclusion Criteria: * There are no exclusion criteria for this registry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Chonbuk National University Hospital

    Iksan, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Dankook University Hospital

    Cheonan, South Korea

  • Gachon Kil Medical Center

    Inchon, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Inje University Ilsan Paik Hospital

    Ilsan, South Korea

  • Inje University Pusan Paik Hospital

    Pusan, South Korea

  • Kwangju Veterans Hospital

    Gwangju, South Korea

  • Kyung Hee University Medical Center

    Seoul, South Korea

  • Presbyterian Medical Center

    Jeonju, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Soon Chun Hyang University Hospital Cheonan

    Cheonan, South Korea

  • St. Carollo Hospital

    Suncheon, South Korea

  • Wonkwang University Hospital

    Iksan, South Korea

  • Yonsei University Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.